Literature DB >> 2384908

Pharmacokinetic behaviour of netobimin and its metabolites in sheep.

C E Lanusse1, R K Prichard.   

Abstract

The pharmacokinetics and the profile of urine excretion of netobimin (NTB) and its metabolites were investigated after its intraruminal (i.r.) and subcutaneous (s.c.) administration to sheep at 20 mg/kg. Plasma and urine concentrations of NTB, albendazole (ABZ), albendazole sulphoxide (ABZSO) and albendazole sulphone (ABZSO2) were measured serially over a 120-h period by HPLC. NTB showed a similar pharmacokinetic profile in both treatments, being detected between 0.5 and 12 h post-treatment, but the tmax was achieved significantly earlier (P less than 0.05) after s.c. treatment. ABZ was detected in plasma only after i.r. treatment, resulting in a low area under the curve (AUC). The peak plasma concentration (Cmax) and AUC for ABZSO and ABZSO2 were significantly higher after i.r. administration of NTB. In both treatments, the ABZSO Cmax was reached earlier than the ABZSO2 Cmax. The ratio of AUC ABZSO2:ABZSO was higher following s.c. administration (1.33) than following i.r. administration (0.35). The percentages of total dose excreted in the urine as NTB, ABZ, ABZSO and ABZSO2 were 17.05 (i.r.) and 8.16 (s.c.). There was a less efficient conversion of NTB into ABZ metabolites after s.c. administration. The detection of ABZ in plasma and the high ABZSO AUC obtained after i.r. treatment may be of major importance for anthelmintic efficacy.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2384908     DOI: 10.1111/j.1365-2885.1990.tb00765.x

Source DB:  PubMed          Journal:  J Vet Pharmacol Ther        ISSN: 0140-7783            Impact factor:   1.786


  7 in total

1.  Transplacental transport of netobimin metabolites in ewes.

Authors:  C Cristofol; A Carretero; M Fernandez; M Navarro; J Sautet; J Ruberte; M Arboix
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1995 Jul-Sep       Impact factor: 2.441

2.  Plasma disposition and faecal excretion of netobimin metabolites and enantiospecific disposition of albendazole sulphoxide produced in ewes.

Authors:  C Gokbulut; V Y Cirak; B Senlik
Journal:  Vet Res Commun       Date:  2006-10       Impact factor: 2.459

3.  Pharmacokinetic behaviour of albendazole sulphoxide enantiomers in male and female sheep.

Authors:  B P Capece; G Castells; F Pérez; M Arboix; C Cristòfol
Journal:  Vet Res Commun       Date:  2000-07       Impact factor: 2.459

4.  Albendazole in environment: faecal concentrations in lambs and impact on lower development stages of helminths and seed germination.

Authors:  Lukáš Prchal; Radka Podlipná; Jiří Lamka; Tereza Dědková; Lenka Skálová; Ivan Vokřál; Lenka Lecová; Tomáš Vaněk; Barbora Szotáková
Journal:  Environ Sci Pollut Res Int       Date:  2016-03-21       Impact factor: 4.223

5.  Bioconversion of netobimin pro-drug by gastrointestinal fluids of ruminants.

Authors:  C E Lanusse; B Nare; L H Gascon; R K Prichard
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1992 Apr-Jun       Impact factor: 2.441

6.  Aspects of the pharmacokinetics of albendazole sulphoxide in sheep.

Authors:  A Goudah
Journal:  Vet Res Commun       Date:  2003-10       Impact factor: 2.459

7.  Influence of diet on the pattern of gastrointestinal biotransformation of netobimin and albendazole sulphoxide in sheep.

Authors:  G Virkel; A Lifschitz; A Pis; C Lanusse
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1999 Jan-Mar       Impact factor: 2.569

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.